Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: Evaluation of its impact within a subgroup of the randomized German CML study IV

Blood

Volumn 115, Issue 10, 2010, Pages 1880-1885

  Saussele, Susanne ^a   Lauseker, Michael ^b   Gratwohl, Alois ^c   Beelen, Dietrich W ^d   Bunjes, Donald ^e   Schwerdtfeger, Rainer ^f   Kolb, Hans Jochem ^g   Ho, Anthony D ^h   Falge, Christiane ⁱ   Holler, Ernst ^j   Schlimok, Günter ^k   Zander, Axel R ^l   Arnold, Renate ^m   Kanz, Lothar ⁿ   Dengler, Robert ^o   Haferlach, Claudia ^p   Schlegelberger, Brigitte ^q   Pfirrmann, Markus ^b   Müller, Martin C ^a   Schnittger, Susanne ^p   Leitner, Armin ^a   Pletsch, Nadine ^a   Hochhaus, Andreas ^a,r   Hasford, Joerg ^b   Hehlmann, Rüdiger ^a   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ KLINIKUM NÜRNBERG   (Germany)

^j UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^k KLINIKUM AUGSBURG   (Germany)

^l UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^m CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁿ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^o Hämatologisch Onkologische Praxis   (Germany)

^p MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^q HANNOVER MEDICAL SCHOOL   (Germany)

^r JENA UNIVERSITY HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; BOSUTINIB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DASATINIB; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; HYDROXYUREA; IDARUBICIN; IMATINIB; INTERFERON; METHOTREXATE; MITOXANTRONE; NILOTINIB; RETINOIC ACID; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT FAILURE; WHOLE BODY RADIATION;

EID: 77950391550     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-237115     Document Type: Article

References (27)

1. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370(9584):342-350.
2. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results: an analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006;91(4):513-521.
3. Bacher U, Klyuchnikov E, Zabelina T, et al. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia - a report from the German Registry covering the period from 1998 to 2004. Ann Hematol. 2009;88(12):1237-1247.
4. Lee SJ, Kukreja M, Wang T, et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008;112(8):3500-3507.
5. Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006;91(4):452-459.
6. Jabbour E, Cortes J, Kantarjian H, et al. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer. 2007;110(2):340-344.
7. Oehler VG, Gooley T, Snyder DS, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007;109(4):1782-1789. (Pubitemid 46239615)
8. Giralt SA, Arora M, Goldman JM, et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. 2007;137(5):461-467. (Pubitemid 46698285)
9. Shimoni A, Leiba M, Schleuning M, et al. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT toxicity in patients with chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemia. Leukemia. 2009;23(1):190-194.
10. O'Brien SG, Guilhot F, Goldman JM, et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM) [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11):186a.
11. Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18(8):1321-1331. (Pubitemid 39136739)
12. Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood. 2007;109(11):4686-4692.
13. Maywald O, Pfirrmann M, Berger U, et al. Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia. Leukemia. 2006;20(3):477-484. (Pubitemid 43291747)
14. Hehlmann R, Saussele S, Lauseker M, et al. Randomized comparison of imatinib 400 mg vs. imatinib + IFN vs. imatinib + araC vs. imatinib after IFN vs. imatinib 800 mg: optimized treatment and survival: designed first interim analysis of the German CML Study IV [abstract]. Blood. 2008;112:Abstract 75a.
15. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998;90(11):850-858. (Pubitemid 28280552)
16. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet. 1998;352(9134):1087-1092. (Pubitemid 28448513)
17. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809-1820.
18. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706. (Pubitemid 29126745)
19. Hughes TP, Deininger MW, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37.
20. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993;82(6):1929-1936.
21. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63(4):789-799.
22. Holowiecki J, Giebel S, Wojnar J, et al. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. Br J Haematol. 2008;142(2):284-292.
23. Lee S, Kim YJ, Chung NG, et al. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2009;115(3):561-570.
24. Mohty M, Szydlo RM, Yong AS, Apperley JF, Goldman JM, Melo JV. Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia. Blood. 2008;112(5):2163-2166.
25. van der Meer A, Schaap NP, Schattenberg AV, van Cranenbroek B, Tijssen HJ, Joosten I. KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients. Mol Immunol. 2008;45(13):3631-3638.
26. Palandri F, Castagnetti F, Testoni N, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica. 2008;93(12):1792-1796.
27. Hehlmann R, Saussele S. Treatment of chronic myeloid leukemia in blast crisis. Haematologica. 2008;93(12):1765-1769.